Biogen: An Undervalued Opportunity In An Overpriced Market

Biogen (NASDAQ: BIIB) saw its share price increase by double digits this past week with the following press release:
FDA Accepts Biogen’s Aducanumab Biologics License Application For Alzheimer’s Disease With Priority Review
The application, under priority revenue, is expected to have a response 7 months from the press release, with a March 7, 2021 action date. The drug, passing through several Phase 3 trails, will be the first approved therapy for Alzheimer’s that doesn’t simply treat the symp…

Click here to view the original article.